ArticleMolecular neurobiology2019
CD73 Downregulation Decreases In Vitro and In Vivo Glioblastoma Growth.
Article in Molecular neurobiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 91 citations in OpenAlex.
- Adenosine Signaling in Primary and Metastatic Brain Tumors: Immune Suppression, Tumor Progression, and Therapeutic Opportunities.Molecular neurobiology · 2026Review
- CD73 inhibitor AB680 suppresses glioblastoma in mice by inhibiting purine metabolism and promoting P2RY12Acta pharmacologica Sinica · 2025Article
- Glioblastoma at the crossroads: current understanding and future therapeutic horizons.Signal transduction and targeted therapy · 2025Review
- Caffeinated and Decaffeinated Yerba Mate (Ilex paraguariensis) Infusion Extracts Alter CD73 and Reduce the Migration and Adhesion of Glioblastoma Cells.Plant foods for human nutrition (Dordrecht, Netherlands) · 2025Article
- Purines and purinergic receptors in primary tumors of the central nervous system.Purinergic signalling · 2025Article
- Assessing Ecto-5'-Nucleotidase/CD73 Expression and Malignancy Parameters in Early- and Late- Passage C6 Glioma Cells.Neurochemical research · 2025Article
- Rosmarinic acid modulates purinergic signaling and induces apoptosis in melanoma cells.Purinergic signalling · 2025Article
- CD73 Molecule Inhibitor Upregulates miR16 Expression in Experimental Glioblastoma and Inhibits Angiogenesis by Targeting VEGF.Journal of molecular neuroscience : MN · 2025Article
- Adenosinergic Signalling in Cervical Cancer Microenvironment.Expert reviews in molecular medicine · 2025Review
- Oncolytic Virotherapy for Glioma: A Bibliometric Roadmap for Multidisciplinary Clinical and Research Strategies.Journal of multidisciplinary healthcare · 2025Article
- Assessing the impact of CD73 inhibition on overcoming anti-EGFR resistance in glioma cells.Oncology research · 2025Article
- Development of a hydrogel-based three-dimensional (3D) glioblastoma cell lines culture as a model system for CD73 inhibitor response study.Biomedical engineering online · 2024Article
- Rational design of siRNA-based delivery systems for effective treatment of brain diseases.Pharmaceutical science advances · 2024Review
- Antitumoral Activity of Cecropia Pachystachya Leaves Extract in Vitro and in Vivo Model of Rat Glioma: Brain and Blood Effects.Molecular neurobiology · 2024Article
- Article
- ENTPD1 (CD39) and NT5E (CD73) expression in human glioblastoma: an in silico analysis.Purinergic signalling · 2024Article
- Influence of Zika virus on the cytotoxicity, cell adhesion, apoptosis and inflammatory markers of glioblastoma cells.Oncology letters · 2024Article
- Effect of adenosine treatment on ionizing radiation toxicity in zebrafish early life stages.Naunyn-Schmiedeberg's archives of pharmacology · 2024Article
- Hypoxia within the glioblastoma tumor microenvironment: a master saboteur of novel treatments.Frontiers in immunology · 2024Review
- CD73: agent development potential and its application in diabetes and atherosclerosis.Frontiers in immunology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastoma is the worst and most common primary brain tumor. Here, we demonstrated the role of CD73, an enzyme responsible for adenosine (ADO) production, in glioblastoma progression. ADO increased glioma cell viability via A1 receptor sensitization. CD73 downregulation decreased glioma cell migration and invasion by reducing metalloproteinase-2 and vimentin expression and reduced cell proliferation by 40%, which was related to necrosis and sub-G1 phase blockage of cell cycle. Those effects also involved the stimulation of Akt/NF-kB pathways. Additionally, CD73 knockdown or enzyme inhibition potentiated temozolomide cytotoxic effect on glioma cells by decreasing the IC
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.